Need an investment idea? Check out S2O Stock Screener. It allows to generate a list of stocks of a particular interest in a matter of seconds!

Market Price

34.34 

-0.74 -2.1%

as of Aug 23 '19

52 Week Range:

33.97 46.47


Stock Analyzer Tutorials

S2O Stock Analyzer - General Info

General Info


type: video (mp4); length: 3:30

Demonstrates how to use Stock Analyzer, shows how to analyze a stock and explains in detail "General Info" section of the Stock Analyzer result page.

S2O Stock Analyzer - Financial Statements

Financial Statements


type: video (mp4); length: 5:10

Explains information presented in the Financial Statements section of the S2O Stock Analyzer: financial statements charts, absolute values and growth rates.

S2O Stock Analyzer - Growth Grade and Financial Ratios

Growth Grade and Financial Ratios


type: video (mp4); length: 5:09

Demonstrates how to use Growth Grade & Financial Ratios section; shows the difference between historical and year-over-year Growth Grade on the real life example.

S2O Stock Analyzer - Value Price

Value Price


type: video (mp4); length: 6:03

Demonstrates how to use Value Price (intrinsic value) and the Graham Number, MOS (margin of safety) and IRT - Investment Recovery Time; explains 3 different projection models used to compute value price - pessimistic, moderate and optimistic.

S2O Stock Analyzer - Price Charts

Price Charts


type: video (mp4); length: 8:34

Demonstrates basic rules of how to read a candlestick chart, long and short term moving averages, stochastic, MACD and relative strength (RS) charts. Explains how bull or bear market condition is computed.

General Info

Pfizer Inc. discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands. The company also provides consumer healthcare products that comprise over-the-counter medicines, including dietary supplement products under the Centrum, Caltrate, and Emergen-C names; pain management products under the Advil and ThermaCare names; gastrointestinal products under the Nexium 24HR/Nexium Control and Preparation H names; and respiratory and personal care products under the Robitussin, Advil Cold & Sinus, and ChapStick names. In addition, it offers products that would lose or have lost marketing patent protection; branded generic products; generic sterile injectable products; biosimilars; and anti-infectives under the Lipitor, Premarin family, Norvasc, Lyrica, Celebrex, Viagra, Inflectra/Remsima, Zyvox, Vfend, Revatio, Inspra, Medrol, Sulperazon, Fragmin, Tygacil, Nivestim, and Retacrit, Ixifi Infliximab BS names. Further, the company is also involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration and/or co-promotion agreements with Bristol-Myers Squibb Company, Astellas Pharma US, Inc., and Merck KGaA; licensing agreement with BionTech AG; and collaboration agreements with Merck & Co., Inc. and Eli Lilly & Company, as well as with Merck KGaA and Nektar Therapeutics to develop a therapy for treating pancreatic cancer. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Financial Statements

The charts below show selected Annual and Quarterly Financial Data.

The purpose of these charts is to discover long and short term change dynamics. When numbers are growing year after year in the annual statements chart, the business become stronger and stronger and this is a good sign.

Quarterly Data Chart can be used to do a short term analysis. It makes sense to pay attention to the quarterly dynamics and do not wait for the next yearly statement. We should be alerted if we see that quarterly numbers are going down.

You can check "Annual Financial Statements" and "Quarterly Financial Statements" sections for exact numbers and growth rates.

Annual Statements

On a charts below the Line shows absolute values and the Bar chart shows Year-Over-Year Growth Rate for selected financial statement item. A consistent GROWTH is generally considered necessary to fund future growth from within a business.
NOTE: Growth Rate is not provided if either the latest period or the year-ago period contains a net loss. (source: WSJ Digest of Earnings)
TIP! move your mouse pointer over bar or a circle on any chart below to see details.

Financial Statements

Income Statement



 

Cash Flow Statement



 

Balance Sheet



 

Liquidity Ratios

Current Ratio


 

Current Ratio measures the ability to meet short term obligations. Generally accepted standard is 2 (current assets should be 2 times or 200% of current liabilities).

Quick Ratio


 

Measures immediate liquidity or the cash available to cover immediate liabilities. A safe margin would be at least 1 (100%).

Financial Leverage


 

Defined as total assets divided by total shareholders' equity. The higher the ratio, the more debt a company uses in its capital structure.

Profitability Ratios

ROA


 

Return on Assets (ROA) measures the income (profit) that is generated by the use of the assets of the business.

ROE


 

Return on Equity (ROE) is a measure of profitability that calculates how many dollars of profit a company generates with each dollar of shareholders equity. ROE is sometimes called "return on net worth."

ROIC


 

The Return on Invested Capital (ROIC) measure gives a sense of how well a company is using its money to generate returns. Some investors use this figure as a final evaluation to determine whether or not to invest in a company.

Annual Statements

Item Name Dec '08 Dec '09 Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Oct '16 Oct '17 Dec '18
Equity (BVPS) 8.52
11.15
10.95
11.88
11.16
12.18
12.39
10.82
10.43
10.16
12.47
growth rate 30.9% -1.8% 8.5% -6.1% 9.1% 1.7% -12.7% -3.6% -2.6% 22.7%
Earnings BIT 9,690.00
10,830.00
9,420.00
12,760.00
12,080.00
15,720.00
15,663.00
13,791.00
14,098.00
14,959.00
15,724.00
growth rate 11.8% -13.0% 35.5% -5.3% 30.1% -0.4% -12.0% 2.2% 6.1% 5.1%
Avg.PE 14.88
14.79
17.15
19.49
19.92
18.55
23.89
26.72
29.21
10.55
23.03
growth rate -0.6% 16.0% 13.6% 2.2% -6.9% 28.8% 11.9% 9.3% -63.9% 118.3%
ROA 7.16
5.33
4.05
5.23
7.79
12.29
5.35
4.13
4.26
12.41
6.73
growth rate -25.6% -24.0% 29.1% 49.0% 57.8% -56.5% -22.8% 3.2% 191.3% -45.8%
ROE 13.24
11.71
9.29
11.78
17.83
27.94
12.38
10.24
11.62
32.58
16.56
growth rate -11.6% -20.7% 26.8% 51.4% 56.7% -55.7% -17.3% 13.5% 180.4% -49.2%
ROIC 10.61
8.46
7.02
8.58
12.90
19.65
8.91
7.11
7.63
19.91
10.98
growth rate -20.3% -17.0% 22.2% 50.4% 52.3% -54.7% -20.2% 7.3% 160.9% -44.9%
Cur. Ratio 1.59
1.66
2.11
2.06
2.14
2.41
2.67
1.49
1.25
1.35
1.57
growth rate 4.4% 27.1% -2.4% 3.9% 12.6% 10.8% -44.2% -16.1% 8.0% 16.3%
Quick Ratio 1.24
1.12
1.51
1.78
1.90
1.79
2.07
1.16
0.94
1.03
0.94
growth rate -9.7% 34.8% 17.9% 6.7% -5.8% 15.6% -44.0% -19.0% 9.6% -8.7%
Leverage 1.93
2.37
2.22
2.29
2.29
2.26
2.38
2.59
2.88
2.41
2.52
growth rate 22.8% -6.3% 3.2% 0.0% -1.3% 5.3% 8.8% 11.2% -16.3% 4.6%
Balance Sheet Dec '08 Dec '09 Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Oct '16 Oct '17 Dec '18
Acct.Receivable 8,958.00
14,645.00
14,612.00
22,438.00
16,845.00
13,981.00
10,967.00
10,838.00
11,266.00
11,271.00
11,399.00
growth rate 63.5% -0.2% 53.6% -24.9% -17.0% -21.6% -1.2% 4.0% 0.0% 1.1%
Acct.Payable 8,603.00
7,508.00
7,367.00
3,210.00
3,620.00
4,536.00
4,656.00
4,674.00
growth rate -12.7% -1.9% -56.4% 12.8% 25.3% 2.7% 0.4%
Cur.Assets 43,076.00
61,670.00
60,468.00
60,817.00
64,831.00
56,244.00
55,595.00
43,804.00
38,949.00
41,142.00
49,926.00
growth rate 43.2% -2.0% 0.6% 6.6% -13.3% -1.2% -21.2% -11.1% 5.6% 21.4%
Total Assets 111,148.00
212,949.00
195,014.00
188,002.00
185,798.00
172,101.00
167,566.00
167,381.00
171,615.00
171,797.00
159,422.00
growth rate 91.6% -8.4% -3.6% -1.2% -7.4% -2.6% -0.1% 2.5% 0.1% -7.2%
Cash 2,122.00
1,978.00
1,735.00
3,182.00
10,081.00
2,183.00
3,343.00
3,641.00
2,595.00
1,342.00
1,139.00
growth rate -6.8% -12.3% 83.4% 216.8% -78.4% 53.1% 8.9% -28.7% -48.3% -15.1%
Inventory 4,381.00
12,403.00
8,405.00
6,610.00
6,076.00
6,166.00
5,663.00
7,513.00
6,783.00
7,578.00
7,508.00
growth rate 183.1% -32.2% -21.4% -8.1% 1.5% -8.2% 32.7% -9.7% 11.7% -0.9%
Cur.Liabilities 27,009.00
37,225.00
28,609.00
28,909.00
29,186.00
23,366.00
21,587.00
29,398.00
31,115.00
30,427.00
31,858.00
growth rate 37.8% -23.2% 1.1% 1.0% -19.9% -7.6% 36.2% 5.8% -2.2% 4.7%
Liabilities 53,592.00
122,935.00
107,201.00
105,812.00
104,538.00
95,794.00
95,944.00
102,383.00
111,775.00
100,141.00
95,664.00
growth rate 129.4% -12.8% -1.3% -1.2% -8.4% 0.2% 6.7% 9.2% -10.4% -4.5%
LT Debt 7,963.00
43,193.00
38,410.00
41,812.00
37,617.00
34,455.00
31,557.00
28,874.00
31,545.00
33,715.00
33,287.00
growth rate 442.4% -11.1% 8.9% -10.0% -8.4% -8.4% -8.5% 9.3% 6.9% -1.3%
Equity 57,556.00
90,014.00
87,813.00
82,190.00
81,260.00
76,307.00
71,272.00
64,694.00
59,520.00
71,287.00
63,388.00
growth rate 56.4% -2.5% -6.4% -1.1% -6.1% -6.6% -9.2% -8.0% 19.8% -11.1%
Common Shares 6,750.00
7,045.00
8,074.00
7,870.00
7,508.00
6,895.00
6,424.00
6,257.00
6,159.00
6,058.00
5,977.00
growth rate 4.4% 14.6% -2.5% -4.6% -8.2% -6.8% -2.6% -1.6% -1.6% -1.3%
Cash Flow Statement Dec '08 Dec '09 Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Oct '16 Oct '17 Dec '18
Capital Expenditures 1,701.00
1,205.00
1,513.00
1,660.00
1,327.00
1,206.00
1,199.00
1,397.00
1,823.00
1,956.00
2,042.00
growth rate -29.2% 25.6% 9.7% -20.1% -9.1% -0.6% 16.5% 30.5% 7.3% 4.4%
Cash Dividends 8,541.00
5,548.00
6,088.00
6,234.00
6,534.00
6,580.00
6,609.00
6,940.00
7,317.00
7,659.00
7,978.00
growth rate -35.0% 9.7% 2.4% 4.8% 0.7% 0.4% 5.0% 5.4% 4.7% 4.2%
Cash From OA 18,238.00
16,587.00
11,454.00
20,240.00
16,746.00
17,684.00
17,084.00
14,688.00
16,192.00
16,802.00
15,827.00
growth rate -9.1% -31.0% 76.7% -17.3% 5.6% -3.4% -14.0% 10.2% 3.8% -5.8%
FCF per Share 2.45
2.18
1.23
2.47
2.09
2.24
2.41
2.22
2.06
2.19
2.61
growth rate -11.0% -43.6% 100.8% -15.4% 7.2% 7.6% -7.9% -7.2% 6.3% 19.2%
Sale Purchase of Stock -8,847.00
-7,660.00
-14,540.00
1,002.00
1,263.00
1,019.00
862.00
growth rate 0.0% 0.0% 100.0% 26.1% -19.3% -15.4%
FCF 16,537.00
15,382.00
9,941.00
18,580.00
15,727.00
16,300.00
15,300.00
13,016.00
13,902.00
14,253.00
13,631.00
growth rate -7.0% -35.4% 86.9% -15.4% 3.6% -6.1% -14.9% 6.8% 2.5% -4.4%
Income Statement Dec '08 Dec '09 Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Oct '16 Oct '17 Dec '18
Sales 48,296.00
50,009.00
65,165.00
61,035.00
54,657.00
51,584.00
49,605.00
48,851.00
52,824.00
52,546.00
53,647.00
growth rate 3.6% 30.3% -6.3% -10.5% -5.6% -3.8% -1.5% 8.1% -0.5% 2.1%
Op.Income 9,694.00
10,827.00
9,471.00
7,860.00
9,021.00
11,410.00
15,663.00
13,791.00
14,098.00
14,959.00
15,724.00
growth rate 11.7% -12.5% -17.0% 14.8% 26.5% 37.3% -12.0% 2.2% 6.1% 5.1%
IBT 9,694.00
10,827.00
9,471.00
11,481.00
11,242.00
15,716.00
12,238.00
8,965.00
8,353.00
12,304.00
11,885.00
growth rate 11.7% -12.5% 21.2% -2.1% 39.8% -22.1% -26.7% -6.8% 47.3% -3.4%
Net Income 8,104.00
8,635.00
8,257.00
7,860.00
9,021.00
11,410.00
9,135.00
6,960.00
7,215.00
21,308.00
11,153.00
growth rate 6.6% -4.4% -4.8% 14.8% 26.5% -19.9% -23.8% 3.7% 195.3% -47.7%
EPS 1.20
1.23
1.02
1.27
1.94
3.19
1.42
1.11
1.17
3.52
1.87
growth rate 2.5% -17.1% 24.5% 52.8% 64.4% -55.5% -21.8% 5.4% 200.9% -46.9%
Gross Profit 40,184.00
41,121.00
50,377.00
48,535.00
44,836.00
41,998.00
40,572.00
39,490.00
40,906.00
41,968.00
42,519.00
growth rate 2.3% 22.5% -3.7% -7.6% -6.3% -3.4% -2.7% 3.6% 2.6% 1.3%
R&D 8,578.00
7,845.00
9,483.00
8,681.00
7,482.00
6,678.00
7,150.00
7,646.00
7,858.00
7,645.00
7,959.00
growth rate -8.6% 20.9% -8.5% -13.8% -10.8% 7.1% 6.9% 2.8% -2.7% 4.1%

Quarterly Statements

Item Name Apr '18 Jul '18 Dec '18 Mar '19 Jun '19
Earnings BIT 4,153.00
3,929.00
3,439.00
4,561.00
4,298.00
growth rate -5.4% -12.5% 32.6% -5.8%
Balance Sheet Apr '18 Jul '18 Dec '18 Mar '19 Jun '19
Acct.Receivable 13,076.00
13,710.00
11,399.00
13,197.00
13,516.00
growth rate 4.9% -16.9% 15.8% 2.4%
Acct.Payable 3,879.00
4,297.00
4,674.00
4,156.00
4,002.00
growth rate 10.8% 8.8% -11.1% -3.7%
Cur.Assets 34,835.00
41,583.00
49,926.00
45,290.00
47,073.00
growth rate 19.4% 20.1% -9.3% 3.9%
Total Assets 164,612.00
167,838.00
159,422.00
155,421.00
156,199.00
growth rate 2.0% -5.0% -2.5% 0.5%
Cash 2,302.00
3,559.00
1,139.00
1,937.00
1,784.00
growth rate 54.6% -68.0% 70.1% -7.9%
Inventory 8,148.00
8,184.00
7,508.00
8,029.00
8,233.00
growth rate 0.4% -8.3% 6.9% 2.5%
Cur.Liabilities 27,365.00
29,013.00
31,858.00
29,423.00
32,030.00
growth rate 6.0% 9.8% -7.6% 8.9%
Liabilities 94,070.00
96,174.00
95,664.00
96,263.00
96,274.00
growth rate 2.2% -0.5% 0.6% 0.0%
LT Debt 32,255.00
34,305.00
33,287.00
35,911.00
36,168.00
growth rate 6.4% -3.0% 7.9% 0.7%
Equity 70,163.00
71,298.00
63,388.00
58,787.00
59,550.00
growth rate 1.6% -11.1% -7.3% 1.3%
Common Shares 465.00
466.00
467.00
468.00
468.00
growth rate 0.2% 0.2% 0.2% 0.0%
Cash Flow Statement Apr '18 Jul '18 Dec '18 Mar '19 Jun '19
Capital Expenditures 386.00
547.00
685.00
460.00
479.00
growth rate 41.7% 25.2% -32.9% 4.1%
Cash Dividends 2,032.00
1,994.00
1,963.00
2,045.00
2,002.00
growth rate -1.9% -1.6% 4.2% -2.1%
Cash From OA 1,983.00
5,259.00
4,738.00
1,698.00
2,611.00
growth rate 165.2% -9.9% -64.2% 53.8%
Sale Purchase of Stock 372.00
growth rate
FCF 1,597.00
4,712.00
4,053.00
1,238.00
2,132.00
growth rate 195.1% -14.0% -69.5% 72.2%
Income Statement Apr '18 Jul '18 Dec '18 Mar '19 Jun '19
Sales 12,906.00
13,298.00
13,977.00
13,118.00
13,264.00
growth rate 3.0% 5.1% -6.2% 1.1%
Op.Income 4,153.00
3,929.00
3,439.00
4,561.00
4,298.00
growth rate -5.4% -12.5% 32.6% -5.8%
IBT 4,127.00
4,177.00
-946.00
4,323.00
4,141.00
growth rate 1.2% -100.0% 100.0% -4.2%
Net Income 3,561.00
4,114.00
-393.00
3,884.00
5,046.00
growth rate 15.5% -100.0% 100.0% 29.9%
EPS
growth rate
Gross Profit 10,372.00
10,626.00
10,936.00
10,707.00
10,714.00
growth rate 2.5% 2.9% -2.1% 0.1%
R&D 1,737.00
1,997.00
2,436.00
1,692.00
1,824.00
growth rate 15.0% 22.0% -30.5% 7.8%

Growth Grade & Financial Ratios

All financial ratios below are calculated based on latest annual statements available and present the most up to date snapshot of a company finances.

Growth Grade

Historical Growth Grade:

F (10.29)

YOY Growth Grade:

F (6.10)

Click on buttons above for detailed yearly growth rates.

Market Ratios

Profitability Ratios

Liquidity Ratios

Efficiency Ratios

Value Price

PE and EPS

Historical Current Forward
PE 21.26 17.64 13.57
EPS / Growth 4.1% 1.95 6.9%

Value Price & Investment Recovery Time

Read more about Stock2Own value price in Stock Market: Fundamental Analysis.

Equity Growth Rate: 1.0%

Estimates Pessimistic Moderate Optimistic My Numbers
Rate of Return 15.0%
MOS Price % 50 %
Future EPS Growth 1.0% 4.0% 4.0%
Future PE 2.00 14.28 14.28
Future EPS 2.15 2.88 2.88
Value Price
MOS %
1.06
-96.9%
10.17
-70.4%
10.17
-70.4%
MOS Price 0.53 5.09 5.09
IRT 16.17 13.20 13.20

Graham Number:

NOTE: The Graham Number applies only to certain types of stocks in combination with a number of other criteria.

Read more about Graham Number in Stock Market: Fundamental Analysis.

Price Chart

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.

Risk / Reward Ratios

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.